What kind of targeted drug is lapatinib?

Lapatinib is an anti-tumor drug and tyrosine kinase inhibitor used to treat patients with advanced or metastatic breast cancer who have previously received chemotherapyHER-positive breast cancer.

Lapatinib was developed by the British company GlaxoSmithKline and its trade name is Telisa. It is a tyrosine kinase inhibitor. It acts by inhibiting the tyrosine kinase activity of human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2). These two receptors play a very important role in the occurrence and development of tumors, especially in breast cancer.

Lapatinib is unique in that it works through multiple pathways and can inhibit breast cancer cells from receiving the signals required for growth, thereby inhibiting or killing tumor cells. It is mainly suitable for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer. Such patients usually have a poor prognosis because high expression of HER2 often indicates easy lymph node metastasis and poor tumor differentiation. Lapatinib inhibits the growth and metastasis of breast cancer cells by competitively binding to HER2, reducing its activity and preventing it from further transmitting signals.

Lapatinib is often used clinically in combination with chemotherapy drugs to improve the therapeutic effect. For example, it can be used in combination with capecitabine to treat advanced or metastatic breast cancer that overexpresses HER2 and has received previous treatments including anthracyclines, paclitaxel, and trastuzumab (Herceptin). Clinical trials have shown that compared with the use of chemotherapy drugs alone, the combined use of lapatinib and chemotherapy drugs can significantly extend the survival time of patients with HER2-positive breast cancer, reduce the size of lesions, relieve pain and other symptoms, and improve the patient's quality of life.

The recommended dose of lapatinib is 1250 mg daily usually taken at least one hour before or one hour after a meal. When used in combination with capecitabine, lapatinib should be taken on days 1 to 21 and capecitabine should be taken in two divided doses on days 1 to 14. When using lapatinib, patients should take the drug strictly in accordance with the doctor's recommendations and prescriptions, and pay close attention to the side effects and adverse reactions of the drug.

The adverse reactions of lapatinib mainly include gastrointestinal reactions (such as nausea, diarrhea, stomatitis and indigestion, etc.), skin reactions (such as dry skin, rash, redness, itching, etc.) and respiratory reactions (such as difficulty breathing, etc.). In addition, after long-term use of lapatinib, breast cancer cells may develop drug resistance, thereby weakening the efficacy of the drug. In order to solve this problem, researchers are actively exploring new treatment strategies, such as the combined application of other targeted therapeutic drugs or immunotherapy.

It is worth noting that lapatinib is only suitable for patients with HER2-positive breast cancer. For HER2-negative patients, lapatinib may not be suitable because its mechanism of action is mainly achieved by inhibiting the HER2 signaling pathway. Therefore, before using lapatinib, the patient's HER2 gene should be tested to ensure that it is overexpressed before the drug can be used.

In general, lapatinib, as a targeted therapy drug, plays an important role in the treatment of breast cancer. It inhibits the activity ofHER2 and EGFR receptors, blocking cell proliferation and differentiation signaling pathways, thereby inhibiting the growth and metastasis of breast cancer. Although lapatinib has problems such as drug resistance and adverse reactions in clinical application, it is still one of the important drugs in the treatment of breast cancer, providing patients with new treatment options and hope.

xa0

Reference materials:https://go.drugbank.com/drugs/DB01259